Hongyang Pi

Hongyang Pi

Auto-generated profile, based on publicly available information

Hongyang Pi

Department of Medicine (H.P., S.G.R., S.A.G., P.J.L.), University of Washington, Seattle

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in Circulation: Heart Failure
Verified
Journal Article
Closed access
HPHongyang Pi
Hongyang Pi
LXLu Xia
Lu Xia
OBOlivier Boucherat
Olivier Boucherat
KSKarthik Suresh
Karthik Suresh
AHAnna R. Hemnes
Anna R. Hemnes
PLPeter J. Leary
Peter J. Leary
BACKGROUND: Pulmonary arterial hypertension (PAH) is a disease of progressive right ventricular (RV) failure with high morbidity and mortality. Our goal is to investigate proteomic features and pathways associated with RV-focused outcomes including mortality, RV dilation, and NT-proBNP (N-terminal pro-B-type natriuretic peptide) in PAH. METHODS: Participants in a single-institution cohort with 3 years of follow-up underwent proteomic profiling of their plasma using 7288 aptamers (targeting 6467 unique human proteins). Partial least squares discriminant analysis was performed to assess global protein variation associated with mortality, RV dilation, and NT-proBNP levels. Differentially abundant proteins and enriched pathways associated with outcomes were identified following baseline adjustments. RV vulnerability models estimated associations for individuals with similar afterload following adjustment for pulmonary vascular resistance. RESULTS: A total of 117 participants with PAH were included. Partial least squares discriminant analysis of the proteome showed clear separation between survivors and nonsurvivors, participants with dilated versus nondilated RVs, and across NT-proBNP levels. Proteins and pathways involving the ECM (extracellular matrix) were upregulated in participants who died during follow-up, those with severe RV dilation, and those with higher levels of NT-proBNP. Pulmonary vascular resistance adjustment reinforced the importance of ECM proteins in the association with RV vulnerability, independent of afterload. These findings were confirmed in independent PAH cohorts with available plasma proteomics and RV tissue gene and protein expression. CONCLUSIONS: Distinct plasma proteomic profiles are associated with mortality, RV dilation, and NT-proBNP in PAH. Proteins and pathways governing tissue remodeling are strongly associated with poor outcomes, may mediate RV vulnerability to right heart failure, and represent promising candidates as biomarkers and potential therapeutic targets.

17 March 2026 in EBioMedicine
Verified
Journal Article
Open access
HPHongyang Pi
Hongyang Pi
LXLu Xia
Lu Xia
SRSamuel G. Rayner
Samuel G. Rayner
JPJeffrey L. Probstfield
Jeffrey L. Probstfield
KBKelley R. Branch
Kelley R. Branch
SGSina A. Gharib
Sina A. Gharib
The significant clinical and molecular heterogeneity of pulmonary arterial hypertension (PAH) poses challenges in identifying effective therapies. Advanced multidimensional profiling offers an opportunity to capture molecular responses and assess biomarker stability, yet its application in randomised trials remains limited. We evaluated the multi-omic profiles of participants with PAH in a randomised, placebo-controlled trial of famotidine. Plasma metabolomic and proteomic profiling was performed at enrolment and 24 weeks. Baseline profiles were compared between treatment arms to assess randomisation balance. Intraclass correlation coefficients quantified within-subject stability over time. Linear regression models adjusting for age, sex, body mass index and PAH aetiology evaluated famotidine's molecular effects. False discovery rate was controlled for multiple comparisons. For the 79 participants, baseline multi-omic profiles were similar between groups. At 24 weeks, 34 and 37 participants remained in the famotidine and placebo groups respectively. The placebo group showed high molecular stability, while greater variability was observed in the famotidine group. Famotidine treatment was associated with significant changes across 191 proteomic pathways (q-value <0.05), but no metabolomic changes remained significant after multiple-testing correction. Integrating multi-omics into a prospective clinical trial is feasible and yields stable longitudinal profiles in the absence of intervention. While famotidine did not yield clinical benefit, associated proteomic changes illustrate how molecular profiling can reveal treatment-related biology and inform future trial design. These findings highlight the broader utility of multi-omics for evaluating drug responses and identifying molecular endotypes in PAH and beyond. US National Institutes of Health.

2 August 2025 in bioRxiv
Verified
Preprint
Open access
KHKellen Hirsch
Kellen Hirsch
CMChristian J Mandrycky
Christian J Mandrycky
IKIsabella Kwan
Isabella Kwan
HPHongyang Pi
Hongyang Pi
WAWilliam A Altemeier
William A Altemeier
SRSamuel G Rayner
Samuel G Rayner
Background: Hemodynamic forces exert a profound influence on endothelial signaling and, when abnormal, contribute centrally to human vascular disease. Pulmonary arterial hypertension (PAH) is characterized by both hemodynamic derangement and pulmonary arterial endothelial cell (PAEC) dysfunction. Despite importance in disease initiation and progression, the combined effects of shear and pressure forces on PAEC biology remain incompletely understood, particularly in the context of PAH. Methods: PAECs obtained at explant from controls and patients with idiopathic PAH or congenital heart disease-associated PAH (CHD-PAH) were cultured in a custom resistor-coupled microfluidic platform and exposed to static, low (3 dyne/cm 2 ), or high (20 dyne/cm 2 ) shear stress under either low or elevated (60 mmHg) pressure. After 24 hours, we assessed cellular morphology and performed transcriptomic analysis via bulk RNA sequencing, incorporating analyses of PAH subtype and donor sex. Results: Morphologically, PAECs (n=18 donors) aligned with flow under high, but not low, shear, and alignment was not significantly altered by disease state or pressure. As expected, shear stress fundamentally reorganized the PAEC transcriptome. The "dose-response" to increasing shear differed across biological pathways in six statistically significant patterns. Increasing shear led to divergence in transcription between control and PAH cells, particularly in pathways involved in immune activation, stress signaling, and vascular remodeling, with subtype differences also observed. Pressure had modest effects on transcription, with CHD-PAH PAECs notably displaying pressure-induced stress and inflammatory signaling. We identified sexual dimorphism in the endothelial shear response, including that male cells under shear enriched for proliferative and angiogenic pathways and female cells for fatty acid metabolism and stress responses. Conclusions: We provide a systems-level overview of how shear and pressure shape PAEC transcription, revealing divergent responses across disease state, PAH subtype, and donor sex. These findings highlight the need for further investigation into mechanosensitive pathways in PAH as potential novel therapeutic targets.

22 May 2026 in Circulation Research
Verified
Journal Article
Closed access
HPHongyang Pi
Hongyang Pi
Sina A. A GharibSina A. A Gharib
Sina A. A Gharib
PLPeter J. Leary
Peter J. Leary

1 May 2023
Verified
Conference Paper
Closed access
LOL.J. Oppegard
L.J. Oppegard
HPH. Pi
H. Pi
JRJ. Robinson
J. Robinson
CHC.T. Hough
C.T. Hough
PLP. Leary
P. Leary

1 October 2025 in Circulation: Heart Failure
Verified
Journal Article
Closed access
HPHongyang Pi
Hongyang Pi
SRSamuel G. Rayner
Samuel G. Rayner
ASAli Shojaie
Ali Shojaie
Sina A. A GharibSina A. A Gharib
Sina A. A Gharib
PLPeter J. Leary
Peter J. Leary
LXLu Xia
Lu Xia